Skip to main
SGMT
SGMT logo

SGMT Stock Forecast & Price Target

SGMT Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sagimet Biosciences Inc has a promising outlook due to the favorable safety profile of its drug candidate denifanstat, which has been highlighted in previous Phase II studies, positioning it as a strong candidate for combination therapies. Additionally, preclinical studies demonstrated denifanstat’s additive efficacy in reducing liver fat and improving liver fibrosis when administered alongside resmetirom, indicating potential therapeutic advantages in treating nonalcoholic steatohepatitis (NASH) and related disorders. The company's focused approach on the development and commercialization of selective fatty acid synthase (FASN) inhibitors reflects a dedication to addressing diseases linked to dysfunctional lipid metabolism pathways, enhancing its long-term growth prospects.

Bears say

Sagimet Biosciences faces potential challenges that could adversely affect its stock performance, primarily due to high turnover in critical regulatory roles such as the CEO and CMO, which may undermine operational stability and investor confidence. Additionally, any emerging efficacy or safety concerns during the clinical development of its lead drug candidate, denifanstat, could significantly impact market perception and share value. These factors combine to create a precarious outlook for the company's financial health and stock performance in the competitive biopharmaceutical landscape.

SGMT has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sagimet Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sagimet Biosciences Inc (SGMT) Forecast

Analysts have given SGMT a Strong Buy based on their latest research and market trends.

According to 7 analysts, SGMT has a Strong Buy consensus rating as of Nov 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sagimet Biosciences Inc (SGMT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.